Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) was used to treat advanced malignancies in 329 evaluable patients. The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow. Oral treatment was repeated at 6-week intervals unless hematologic toxicity intervened. There were four complete responses: two in ovarian cancer, one with small cell carcinoma of the lung, and one with melanoma. Tumor response greater than 50% reduction in tumor size occurred in 39 patients (11.9%) while stable disease (no change or decrease or increase of less than 50% in tumor size) was noted in 152 patients (46.2%). Tumor progression occurred in 130 cases. Melanomas and ovarian and lung cancers had the highest response rates. Bone marrow depression was the major side effect of treatment; there was a significant positive correlation between the severity of leukopenia and thrombocytopenia and tumor response to treatment.
D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008130:Lomustine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D009607:Nitrosourea Compounds; D008130:Lomustine